Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Chicago Bayer |
---|---|
Information provided by: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT00449280 |
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib.
This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.
Condition | Intervention | Phase |
---|---|---|
Advanced Solid Tumor |
Drug: Sorafenib Drug: Rapamycin |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Pharmacokinetics Study |
Official Title: | A Drug Interaction Study of Sorafenib (BAY 43-9006 Tosylate) and Rapamycin in Patients With Advanced Malignancies |
Estimated Enrollment: | 24 |
Study Start Date: | November 2006 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
|
Drug: Sorafenib
400mg BID (200 mg twice daily)
Drug: Rapamycin
30mg once weekly
|
B: Experimental
Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
|
Drug: Sorafenib
400mg BID (200 mg twice daily)
Drug: Rapamycin
3mg once daily
|
C: Experimental
Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
|
Drug: Sorafenib
400mg BID (200 mg twice daily)
Drug: Rapamycin
30mg once weekly
|
D: Experimental
Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
|
Drug: Sorafenib
400mg BID (200 mg twice daily)
Drug: Rapamycin
3mg once daily
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have adequate organ and marrow function as defined below:
Exclusion Criteria:
United States, Illinois | |
University of Chicago | |
Chicago, Illinois, United States, 60637 |
Principal Investigator: | Ezra Cohen, MD | University of Chicago |
Responsible Party: | University of Chicago ( Ezra Cohen, MD ) |
Study ID Numbers: | 14908B |
Study First Received: | March 16, 2007 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00449280 History of Changes |
Health Authority: | United States: Food and Drug Administration |
metastatic advanced disease phase I |
Sirolimus Anti-Infective Agents Anti-Bacterial Agents Immunologic Factors |
Antifungal Agents Protein Kinase Inhibitors Immunosuppressive Agents Sorafenib |
Sirolimus Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors Antibiotics, Antineoplastic |
Immunosuppressive Agents Protein Kinase Inhibitors Pharmacologic Actions Anti-Bacterial Agents Therapeutic Uses Antifungal Agents Sorafenib |